COST ANALYSIS OF TAXANE-BASED AND CISPLATIN-BASED CHEMOTHERAPY REGIMENS FOR EPITHELIAL OVARIAN CANCER IN DHARMAIS NATIONAL CANCER HOSPITAL
Objective: This exploratory study aimed to evaluate and compare the treatment costs of taxane-based versus cisplatin-based chemotherapy.
Methods: This study used data from the medical and financial records of ovarian cancer patients who were admitted to Dharmais National
Cancer Hospital (RSKD) between 2008 and 2012 and subsequently underwent surgery and were treated with chemotherapy. Data were analyzed
using descriptive analysis, and a Kaplanâ€“Meier graph was plotted to compare the survival of the patients in the taxane-based and cisplatin-based
Results: Of 41 patients, treatment costs were available for nine patients who had undergone taxane-based chemotherapy and for 31 patients who had
undergone cisplatin-based chemotherapy. In general, surgical procedures accounted for the highest proportion of the treatment costs, followed by
chemotherapy. Taxane-based chemotherapy (six cycles) was 4 times more expensive than cisplatin-based therapy. The pre- and post-chemotherapy
costs of care among those treated with the taxane-based regimen were 3-4 times more expensive than those of the patients who received cisplatinbased
treatment. The disease-free recurrence duration of the patients treated with taxane was longer (median=18 months) than that of the patients
treated with cisplatin (median=5 months).
Conclusions: Taxane-based therapy increased the disease-free recurrence duration of the patients, with disease-free recurrence 3 times longer than
that of the patients treated with the cisplatin-based regimen. However, the treatment costs of the taxane-based regimen were 4 times higher than
those of the cisplatin-based treatment.
ovarian cancer: A proposed unifying theory. Am J Surg Pathol
2. Jelovac D, Armstrong DK. Recent progress in the diagnosis and
treatment of ovarian cancer. CA Cancer J Clin 2011;61(3):183-203.
3. Hollis RL, Gourley C. Genetic and molecular changes in ovarian
cancer. Cancer Biol Med 2016;13(2):236-47.
4. Parkin DM, Pisani P, Ferlay J. Global Cancer Statistics. CA Cancer J
5. Ferlay J, Bray F, Pisani P, Parkin DM. GLOBOCAN 2002: Cancer
incidence, mortality and prevalence worldwide. Lyon: IARC
6. Aziz MF. Gynecological cancer in Indonesia. J Gynecol Oncol
7. Ubiet JF. Angka kesintasan kanker ovarium di RS Kanker Dharmais.
Thesis. Depok: Universitas Indonesia;2009. [In Indonesia].
8. Ozols RF, Bundy BN, Greer BE, Fowler JM, Clarke-Pearson D,
Burger RA, et al. Phase III trial of carboplatin and paclitaxel compared
with cisplatin and paclitaxel in patients with optimally resected stage III
ovarian cancer. J Clin Oncol 2003;21(7):3194-200.
9. Prat A, parera M, Del Campo JM. Prognostic role of CA-125 nadir in
stage IV epithelial ovarian cancer. J Clin Oncol 2008;26(10):1771-2.
10. Inciura A, Simavicius A, Juozaityte E, Kurtinaitis J, Nadisauskiene R,
Svedas E, et al. Comparison of adjuvant and neoadjuvant chemotherapy
in the management of advanced ovarian cancer: A retrospective study
of 574 patients. BMC cancer 2006;6(1):153.
11. Cristea M, Han E, Salmon L, Morgan RJ. Review: Practical
considerations in ovarian cancer chemotherapy. Ther Adv Med Oncol
12. Rumah Sakit Kanker Dharmais. Gynaecological cancer protocol.
Jakarta: RSKD; 2001. [In Indonesia].
13. Reeder CE, Gordon D. Managing oncology costs. Am J Manag Care
14. ExpÃ³sito J, HernÃ¡ndez J, FeijÃ³o AF, Nieto T, Briones E. New
chemotherapy treatments in advanced cancer patients an easily
applicable evaluation of clinical efficacy and cost-effectiveness. Acta
15. Sfakianos GP, Havrilesky LJ. A review of cost-effectiveness studies in
ovarian cancer. Cancer Control 2011;18(1):59-64.
16. Cella D, Peterman A, Hudgens S, Webster K, Socinski MA.
Measuring the side effects of taxane therapy in oncology. Cancer
17. Smith LH. Early clinical detection of ovarian cancer: A review of the
evidence. Expert Rev Anticancer Ther 2006;6(7):1045-52.
18. McGuire III WP, Markman M. Primary ovarian cancer chemotherapy:
Current standards of care. Br J Cancer 2003;89(Suppl 3):S3-8.